Chimerix Inc (CMRX)
$8.53 +0.01 (0.12%)Market Cap | 797.33M |
Revenue (ttm) | 210,000.00 |
Net Income (ttm) | -88.39M |
EPS (ttm) | N/A |
PE Ratio | 0.00 |
Forward PE | N/A |
Profit Margin | -42,090.48% |
Debt to Equity Ratio | 0.00 |
Volume | 1,013,300 |
Avg Vol | 4,460,456 |
Day's Range | N/A - N/A |
Shares Out | 93.80M |
Stochastic %K | 100% |
Beta | -0.18 |
Analysts | Sell |
Price Target | $8.54 |
Latest News on CMRX


Mar 21, 2025, 6:00 AM EDT - 14 days ago
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results


Mar 7, 2025, 4:01 PM EST - 27 days ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2025, 11:20 AM EST - 4 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Mar 5, 2025, 8:41 AM EST - 4 weeks ago
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

Mar 5, 2025, 7:00 AM EST - 4 weeks ago
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

Feb 20, 2025, 5:25 PM EST - 6 weeks ago
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients

Jan 29, 2025, 4:15 PM EST - 2 months ago
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

Dec 30, 2024, 7:00 AM EST - 3 months ago
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Dec 11, 2024, 2:19 PM EST - 4 months ago
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 9, 2024, 4:01 PM EST - 4 months ago
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Nov 1, 2024, 7:00 AM EDT - 5 months ago
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

Oct 18, 2024, 4:31 PM EDT - 5 months ago
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2024, 7:00 AM EDT - 11 months ago
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

May 1, 2024, 7:00 AM EDT - 1 year ago
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Apr 24, 2024, 7:00 AM EDT - 1 year ago
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Feb 29, 2024, 7:00 AM EST - 1 year ago
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Feb 22, 2024, 7:00 AM EST - 1 year ago
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Dec 4, 2023, 7:00 AM EST - 1 year ago
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Nov 16, 2023, 7:00 AM EST - 1 year ago
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Nov 2, 2023, 7:00 AM EDT - 1 year ago
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Oct 26, 2023, 7:00 AM EDT - 1 year ago
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023


Aug 3, 2023, 7:00 AM EDT - 1 year ago
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Jul 27, 2023, 7:00 AM EDT - 1 year ago
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

Jun 27, 2023, 4:05 PM EDT - 1 year ago
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

May 25, 2023, 7:00 AM EDT - 2 years ago
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

May 4, 2023, 7:00 AM EDT - 2 years ago
Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

Apr 27, 2023, 7:00 AM EDT - 2 years ago
Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Apr 18, 2023, 4:01 PM EDT - 2 years ago
Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

Mar 2, 2023, 7:00 AM EST - 2 years ago
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Jan 5, 2023, 7:00 AM EST - 2 years ago
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 8, 2022, 5:00 PM EST - 2 years ago
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update